Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Up 53.3% in December

Repare Therapeutics Inc. (NASDAQ:RPTX) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,300,000 shares, an increase of 53.3% from the December 15th total of 847,800 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 380,100 shares, the short-interest ratio is presently 3.4 days.

Institutional Trading of Repare Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC raised its position in shares of Repare Therapeutics by 1,471.7% during the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after buying an additional 7,800 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after acquiring an additional 4,000 shares in the last quarter. XTX Topco Ltd acquired a new position in Repare Therapeutics in the 2nd quarter valued at approximately $110,000. Exchange Traded Concepts LLC lifted its position in shares of Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after acquiring an additional 8,809 shares during the period. Finally, Stifel Financial Corp grew its holdings in shares of Repare Therapeutics by 36.4% during the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after purchasing an additional 13,800 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Price Performance

RPTX stock remained flat at $1.28 on Friday. 189,282 shares of the company were exchanged, compared to its average volume of 500,189. The stock has a market capitalization of $54.41 million, a price-to-earnings ratio of -0.64 and a beta of 0.88. Repare Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $8.49. The company has a 50 day simple moving average of $2.28 and a two-hundred day simple moving average of $2.97.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RPTX shares. Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a research report on Friday, November 8th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Finally, Stifel Nicolaus decreased their target price on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 13th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.